VJOncology Podcast

Latest Episodes:

Bladder Cancer Awareness Month Part I: The past, present, and future of ADCs May 03, 2024

Show notes

In this podcast, we commemorate Bladder Cancer Awareness Month in May with a special limited series, where we invite a special guest to discuss and share their expert perspectives within this ever evolving field. This week, Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, will be talking about antibody-drug conjugates, which have made a big impact in the treatment landscape of bladder cancer and other solid tumors. He will provide his thoughts on the approval of enfortumab vedotin, managing toxicities, and the future of ADCs.

The post Bladder Cancer Awareness Month Part I: The past, present, and future of ADCs appeared first on VJOncology.

BTOG 2024 Highlights Apr 26, 2024

Show notes

Tune in to an insightful podcast hosted by VJOncology, featuring experts from BTOG 2024 discussing advancements in lung cancer research.

Prof. Charles Swanton (Francis Crick Institute, London, UK) delves into the link between air pollution and cancer development. Dr Thomas Newsom-Davies (Chelsea and Westminster Hospital NHS Foundation Trust, London, UK) highlights progress in TNM staging and immunotherapy. Dr Mariana Brandao (Institute Jules Bordet, Brussels, Belgium) addresses operability in non-small cell lung cancer, stressing the need for thorough assessments. Dr Robert Rintau (University of Cambridge & Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK) discusses implications of improved survival rates and evolving treatments. Dr Crispin Hiley (UCL, London, UK) reflects on the HIT-Meso trial, while Prof. Sanjay Popat (The Royal Marsden NHS Foundation Trust, London, UK) underscores the success of BTOG 2024 in representing multidisciplinary teams. Explore the dynamic landscape of lung cancer treatment and research. Listen now for valuable insights.

The post BTOG 2024 Highlights appeared first on VJOncology.

Highlights from AACR 2024: KRYSTAL-1, FLAURA2, and EDGE Apr 12, 2024

Show notes

This week, we cover key updates from the American Association for Cancer Research (AACR) 2024 Annual Meeting, held in San Diego, CA. Hear from Scott Koptez, The University of Texas MD Anderson Cancer Center, Houston, TX, Rebecca Porter, Dana-Farber Cancer Institute, Boston, MA, Pasi Janne, Dana-Farber Cancer Institute, Boston, MA, and Elizabeth Swisher, Fred Hutchinson Cancer Center, Seattle, CA, as they discuss takeaways from the meeting.

The post Highlights from AACR 2024: KRYSTAL-1, FLAURA2, and EDGE appeared first on VJOncology.

Updates in immunotherapy for head and neck cancer Mar 28, 2024

Show notes

In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat head and neck cancer. This week we will be joined by Nicolas Mach, MD, Hôpitaux Universitaires de Genève, Geneva, Switzerland; Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH; Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH; Ari Rosenberg, MD, University of Chicago, Chicago, IL and Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA.

We will hear about the results of the SAKK 11/16 trial (NCT02999646) of the MVX-ONCO-1 vaccine, a Phase I dose expansion trial (NCT04429542) of BCA101, a bifunctional EGFR/TGFβ inhibitor, with pembrolizumab, and increasing T-cell responses in HPV-positive head and neck cancer with TheraT vectors, as well as other novel immunotherapy approaches.

For other head and neck cancer news, head over to our Head and Neck Cancer Channel. Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.

The post Updates in immunotherapy for head and neck cancer appeared first on VJOncology.

Updates in immunotherapy for skin cancer Mar 22, 2024

Show notes

In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat skin cancer. This week, we will be joined by Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA; Paolo Ascierto, MD, Istituto Tumori Fondazione Pascale, Naples, Italy; Georgina Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia; and Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands.

We will hear on the impact of T-Cell therapies, such as lifileucel, in patients with melanoma; results of the 7-year CheckMate 238 trial (NCT02388906) of nivolumab; effective sequencing of treatments in the SECOMBIT trial (NCT02631447); and challenges in managing immunotherapy related adverse events.

If you would like to learn more about the recent approval of lifileucel by the FDA, you can find our feature article here. For other skin cancer news, be sure to visit our dedicated Skin Cancer Channel.

Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.

The post Updates in immunotherapy for skin cancer appeared first on VJOncology.

Highlights in colorectal cancer at ASCO GI 2024 Mar 08, 2024

Show notes

In this week’s podcast by VJ Oncology, six leading experts share their insights on cutting-edge developments in colorectal cancer screening and treatment, drawn from highlights of the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. One key focus was the rapid evolution of non-invasive blood-based tests for colorectal cancer screening, as discussed by Aasma Shauka from New York University. Further, Theodore R. Levin from Kaiser Permanente shared the effectiveness of stool-based testing in achieving high adherence rates for colorectal cancer screening. Meanwhile, Sebastian Stintzing from Charité – Universitätsmedizin Berlin analyzed the Phase II FRASCO2 trial, demonstrating the benefit of fruquintinib for heavily pre-treated patients with refractory metastatic colorectal cancer in a Q-TWIST analysis. Edward Esplin from Invitae speaks on the potential of personalized monitoring tests in early-stage colorectal cancer treatment and Van K. Morris from the University of Texas analyzing a prospective phase 2 clinical trial for previously treated metastatic colorectal cancer. Finally, Anwar Saeed’s discusses the rationale behind STELLAR-303 trial aiming to address unmet needs of patients with specific types of metastatic colorectal cancer.

The post Highlights in colorectal cancer at ASCO GI 2024 appeared first on VJOncology.

Targeted therapies for lung cancer at TTLC 2024 Mar 01, 2024

Show notes

This week, we cover interesting research from TTLC 2024, focusing on innovative treatments for lung cancer. Starting off, Bruna Pellini from Moffitt Cancer Center, FL, talks about the utility of circulating tumor DNA as a biomarker of progression in lung cancer, her latest findings from notable Phase III trials and ongoing studies looking into increasing treatment based on this biomarker.

Next, Monica Chen from Memorial Sloan Kettering Cancer Center, NY, discusses the role of osimertinib with chemotherapy as initial treatment for patients with metastatic EGFR mutant lung cancers with concurrent TP53 and RB1 alterations from a clinical trial perspective.

Our final speaker, Timothy Burns from University of Pittsburgh, PA, shares detailed insights into non-TKI treatment options for EGFR mutant lung cancer. He discusses the exciting prospects of upcoming studies, potential FDA approvals and the integrated role of immuno-modulatory agents in EGFR mutant patients.

Our podcast aims to deliver the latest and most intriguing updates in the field directly to you. Follow us on Twitter at @vjoncology and visit our website for the newest trends.

The post Targeted therapies for lung cancer at TTLC 2024 appeared first on VJOncology.

Updates in invasive lobular carcinoma (ILC) Feb 23, 2024

Show notes

Invasive lobular carcinoma (ILC) poses unique challenges in breast cancer management. Its subtle presentation and distinct biological behavior demand a nuanced approach from healthcare professionals. In this podcast, we delve into the epidemiology, pathology, diagnostic methods, treatment modalities, and emerging research surrounding ILC. By comprehensively understanding this subtype, healthcare professionals can optimize patient care and ultimately improve patient outcomes. In this enlightening podcast from VJ Oncology, join our distinguished guests, Jason Aboudi Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Fresia Pareja, MD, Memorial Sloan Kettering Cancer Center, New York, NY, as they delve into the complexities of ILC.

The post Updates in invasive lobular carcinoma (ILC) appeared first on VJOncology.

Esophageal and gastric cancer highlights from ASCO GI 2024 Feb 16, 2024

Show notes

In this podcast, we will discuss key insights from the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. Topics include updates in the KEYNOTE-811, MATTERHORN, and CheckMate 649 trials, as well as the use of circulating free DNA analysis in esophagogastric cancer and the evolving landscape of treatment of HER2-positve metastatic gastric cancer. Additionally, hear on a pilot PET study using the positron-emitting agent 18F-BMS-986229 for PD-L1 imaging in advanced esophagogastric cancer and a retrospective investigation into the concordance between three PD-L1 scoring methods and their association with clinical outcomes in RATIONALE-302.

Tune in to hear perspectives from experts such as Yelena Y. Janjigian (Memorial Sloan Kettering Cancer Center, New York, NY), Samuel Louis Cytryn (Memorial Sloan Kettering Cancer Center, New York, NY), Kohei Shitara (National Cancer Center Hospital East, Kashiwa, Japan), Ken Kato (National Cancer Center Hospital, Tokyo, Japan) and Nataliya V. Uboha (University of Wisconsin Carbone Cancer Center, Madison, WI).

The post Esophageal and gastric cancer highlights from ASCO GI 2024 appeared first on VJOncology.

Key updates at ASCO GU 2024 Feb 09, 2024

Show notes

In this podcast, we will discuss key insights from the 2024 ASCO Genitourinary (GU) Cancers Symposium held in San Francisco, CA. Topics include updates in the AMBASSADOR, CONTACT-2, and CLEAR trials, as well as why BCG-unresponsive patients with non-muscle invasive bladder cancer refuse cystectomy and the emerging role transperineal prostate biopsies. Tune in to hear perspectives from experts such as Andrea Apolo (National Institutes of Health, Bethesda, MD), Kim Chi (BC Cancer Vancouver Centre, Vancouver, Canada), Viktor Grünwald (University Hospital Essen, Essen, Germany), Joseph Jacob (Upstate Medical University, Syracuse, NY), and Jim Hu (Weill Cornell Medicine, New York, NY).

The post Key updates at ASCO GU 2024 appeared first on VJOncology.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected